New hepatitis b drug studied in Liver-Impaired patients
NCT ID NCT07342868
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a single dose of the drug pevifoscorvir sodium in 16 adults: 8 with moderate liver impairment and 8 healthy volunteers. Researchers want to see how the drug is processed in the body and if it is safe. The goal is to gather information for future dosing recommendations in people with chronic hepatitis B.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pevifoscorvir sodium (ALG-000184)
- What this could lead to
- If successful, this study could help determine safe dosing of pevifoscorvir sodium for chronic hepatitis B patients with liver problems.
- What could go wrong
- This is a very early Phase 1 trial with only 16 people. It focuses on how the drug moves through the body, not on curing disease. Results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPAITITIS B INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States